Aldaver
A medical technology startup developing hyper-realistic, biopolymer-based artificial organ simulators designed for high-fidelity surgical training and medical device validation.
- CEO / Founder
- Kim Jin-oh, Steve Park
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $9.6M
- Latest Round
- Series A
- Key Investors
- SL Investment, Korea Investment Partners, Daily Partners, KB Investment, Ascendo Ventures, Bluepoint Partners
Technology & Products
Key Products
Biopolymer-based artificial organ simulators for surgical training and medical device validation, including models for urological and vascular procedures, skin, and benign prostatic hyperplasia (BPH) simulators. Also offers an online mall for products.
Technological Advantage
Leverages the founder's expertise in 'electronic skin' and flexible electronics to integrate sensory feedback into simulators, bridging the gap between static plastic models and living tissue.
Differentiation
Value Proposition
Provides a high-fidelity, ethical alternative to animal testing and human cadavers by mimicking the exact mechanical resistance and electrical conductivity of living human tissue.
How They Differentiate
Aldaver differentiates through its proprietary 'Liquid-to-Solid' biopolymer technology and 'electronic skin' expertise. Unlike traditional plastic models, Aldaver’s simulators mimic the exact electrical conductivity and mechanical resistance of living tissue, allowing for the realistic use of electrosurgical and robotic tools that typically fail on standard synthetic materials.
Market & Competition
Target Customers
Medical schools, teaching hospitals, surgical training centers, and global medical device manufacturers (R&D and sales divisions).
Industry Verticals
["Medical Technology (MedTech)","Healthcare Education","Surgical Robotics","Medical Device Manufacturing"]
Competitors
CAE Healthcare, IngMar Medical, SynDaver Labs
Growth & Milestones
Growth Metrics
Achieved a 4.4x valuation increase between Pre-Series A and Series A; established a dedicated manufacturing facility in the Osong High-Tech Medical Complex.
Major Milestones
["Recipient of the CES 2023 Innovation Award for realistic medical simulators","Successfully developed 'Liquid-to-Solid' biopolymer technology for haptic organ mimicry","Completed $8.4M Series A funding round in January 2025","Established specialized production line at Osong High-Tech Medical Complex"]
Notable Customers
Medical schools, teaching hospitals, surgical training centers, global medical device manufacturers (R&D and sales divisions). Collaborations with VRiMS and Società Italiana di Andrologia (SIA).